In today’s briefing:
- ChiNext/ChiNext50 Index Rebalance Preview: Potential Changes & Basket Performance
- Kelun-Biotech (科伦博泰) IPO Trading: Lukewarm Demand but Peers Have Done Well Recently
- Chindata (CD US): China Merchants Capital’s Rival Privatisation Offer
- [Alibaba (BABA US, BUY, TP US$116) Target Price Change]: CMR Improves on Expanded Merchant Base
- Pre-IPO HighTide Therapeutics – Its Outlook in NASH Field Is Not Optimistic, with High Risks
- Morning Views Asia: China SCE, Hopson Development, Reliance Industries, Sino-Ocean Service
- PDD Holdings Inc.: 3 Major Factors Responsible For Its Recovery – Key Drivers
- Syngenta Pre-IPO – The Positives – Giant in the Agriculture Industry Set to Benefit from Policies
- Unisound AI Technology Pre-IPO Tearsheet
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
ChiNext/ChiNext50 Index Rebalance Preview: Potential Changes & Basket Performance
- One third of the way through the review period, we forecast 10 changes for the ChiNext Index (SZ399006 INDEX EQUITY) and 5 changes for the ChiNext 50 Index in December.
- Passive trackers are estimated to trade around +/-0.5 days ADV on most of the potential adds/deletes, though there are some deletes that will have over 1 day ADV to sell.
- The potential inclusion to one or both indices have outperformed the potential deletes by a huge margin in the 5 months. We’d wait for a pullback to re-enter positions.
Kelun-Biotech (科伦博泰) IPO Trading: Lukewarm Demand but Peers Have Done Well Recently
- Kelun-Biotech raised HKD 1,259m (USD 161m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday, July 10th.
- In our previous note, we looked at the company’s business lines of ADC products. We were of the view that the IPO is fairly priced, at best.
- In this note, we provide an update for the IPO before trading debut.
Chindata (CD US): China Merchants Capital’s Rival Privatisation Offer
- China Merchants Capital (CMC) disclosed a competing preliminary non-binding proposal to acquire Chindata Group (CD US) at US$9.20 per ADS, a 15.0% premium to Bain Capital’s US$8.00 per ADS offer.
- Astonishingly, Chindata did not publicly disclose the CMC offer, which was sent to the special committee on 9 June, i.e., 34 days ago.
- CMC must get Bain Capital’s support due to its 92.34% voting rights. The presence of a credible competing proposal will require Bain Capital to match CMC’s offer.
[Alibaba (BABA US, BUY, TP US$116) Target Price Change]: CMR Improves on Expanded Merchant Base
- We expect BABA to report C2Q23 (F1Q24) top-line and non-IFRS net income 2% and 21.5% vs. consensus. For C2Q23, we raised (1) Taobao/Tmall GMV/CMR estimates due to return of merchants,
- (2) International Commerce and Cainiao revenue estimates, and (3) EBITA margin estimates for all groups except cloud. We maintain our BUY rating and raise TP to US$ 116 TP,
- Due to 1) merchants return to Taobao/Tmall; 2) independent listing of groups; and 3) improved incentive structure after the organizational change.
Pre-IPO HighTide Therapeutics – Its Outlook in NASH Field Is Not Optimistic, with High Risks
- The mechanism of NASH has not yet been accurately determined. Among the major players, FDA has postponed the approval of OCA (FXR) for NASH. THR-β is currently the most promising.
- HighTide claims that HTD1801 is able to achieve the goal of improving effectiveness and reducing toxicity. However, HTD1801 hasn’t reached pathological endpoints. We’ll have to wait for future clinical data.
- This Company actually has high risk due to cash shortage and uncertain R&D progress, which could lead to lower-than-expected stock price performance. We are conservative about HighTide based on analysis.
Morning Views Asia: China SCE, Hopson Development, Reliance Industries, Sino-Ocean Service
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
PDD Holdings Inc.: 3 Major Factors Responsible For Its Recovery – Key Drivers
- PDD delivered an all-around beat in the previous quarter and the company saw clear recovery trends.
- Revenue increased in the quarter and contributed to a total of RMB37.6 billion.
- PDD has also launched its electronic shopping season and invested millions of RMB for promoting universal and high-quality access to reading.
Syngenta Pre-IPO – The Positives – Giant in the Agriculture Industry Set to Benefit from Policies
- Syngenta Group (1844795D CH) is looking to raise around US$9.2bn in its upcoming China A-share IPO.
- Syngenta Group (Syngenta) is one of the largest agricultural firms globally, developing, producing and commercializing a portfolio of crop protection, seeds, crop nutrition products.
- In this note, we will talk about the positive aspects of the deal.
Unisound AI Technology Pre-IPO Tearsheet
- Unisound AI Technology (1053075D CH) is looking to raise at least US$300m in its upcoming HK IPO. The deal will be run by CICC and Haitong International.
- The firm offers AI solutions centered around its computing cluster, scheduling computing power for machine learning tasks. It provides support to the development, optimization and commercialization of frontier AI models.
- Its computing cluster currently harbors a computing power of over 200 peta floating point operations per second (PFLOPS), and a storage capacity of over 1.6 petabytes (PB).